Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate

     Ventana and Biocare Medical sign p63 license agreement to aid in the
       differential diagnosis of benign and malignant prostate lesions

PR Newswire

TUCSON, Ariz., Feb. 26, 2013

TUCSON, Ariz., Feb. 26, 2013 /PRNewswire/ --Ventana Medical Systems, Inc.
(Ventana), a member of the Roche Group and Biocare Medical, LLC (Biocare)
today announced that they have entered into a non-exclusive license agreement
to allow Biocare access to certain patents and materials related to p63
diagnostics in the research and IVD field. In parallel, Biocare and AsymmetRx
Medical, Inc. (AsymmetRx) have settled their dispute as it relates to the p63
technology. As part of the settlement, Biocare has gained a worldwide license
through Ventana to distribute p63 (4A4) mouse monoclonal primary antibody in
both the research and IVD market and AsymmetRx has agreed to terminate all
patent infringement litigation. AsymmetRx holds the exclusive, worldwide
license under the Harvard Medical School patent filings for the use of the p63
antibody as an aid in the diagnosis of prostate and other cancers. Financial
terms of the license and settlement were not disclosed.


"Our mission is to improve the lives of all patients afflicted with cancer,"
says Mara Aspinall, President, Ventana Medical Systems, Inc. "Through our
licensing program, we make the most advanced products in the industry
available to those in need and help ensure the standardization of diagnostic
results to benefit patients."

The p63 gene was discovered in the Harvard lab of Dr. Frank McKeon and the p63
cancer diagnostic test was invented by a collaboration of labs at Harvard
Medical School, Dana Farber Cancer Institute and the Brigham and Women's
Hospital. p63 protein is highly expressed in prostate, breast, bladder, and
lung tissue and the p63 (4A4) mouse monoclonal antibody has been extremely
useful in the differentiation of benign and malignant lesions in conjunction
with morphological findings. Numerous articles in top clinical journals have
cited the accuracy and utility of p63 as an aid in prostate cancer diagnosis,
and it has become the gold standard used by leading hospitals, laboratories
and experts worldwide.

"Including p63 in our lung, prostate and breast panels really empowers our
Multiplex IHC platform to aid pathologists in making critical decisions and
solidifies our passion for patient care and the ability to fight cancer one
slide at a time," says Roy Paxton Yih, President & CEO, Biocare Medical, LLC.

"Prostate cancer is one of the most difficult cancers to diagnose, and the
p63-based test adds a significant advantage to making the correct diagnosis.
We are very excited about our agreement with Ventana, and now Biocare, as it
will provide a platform to bring the p63 diagnostic tests to patients
worldwide," says Peter F. McKeon, President, AsymmetRx Medical, Inc.

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member
of the Roche Group, innovates and manufactures instruments and reagents that
automate tissue processing and slide staining for cancer diagnostics. VENTANA
solutions are used in clinical histology and drug development research
laboratories worldwide. The company's intuitive, integrated staining, workflow
management platforms, and digital pathology solutions optimize laboratory
efficiencies to reduce errors, support diagnosis and inform treatment
decisions for anatomic pathology professionals. Together with Roche, VMSI is
driving Personalized Healthcare through accelerated drug discovery and the
development of "companion diagnostics" to identify the patients most likely to
respond favorably to specific therapies.

VENTANA and the VENTANA logo are trademarks of Roche.

Visit to learn more.

Ventana Medical Systems, Inc.
Empowering | Innovation

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
Request High Resolution Files

About Biocare Medical, LLC
Biocare Medical, LLC is an innovator in developing and supplying world class
automated immunohistochemistry (IHC) instrumentation, and the full range of
reagents for IHC lab testing. Biocare Medical is the market leader in
simultaneous Multiplex IHC and antibody development, which aids in the
assessment of clinical cases and accelerates turnaround time. The company's
customers include clinical histology laboratories, pharmaceutical companies,
CROs, and biotechnology companies as well as academic, government, military,
and other non-profit laboratories. Biocare Medical offers an expanding
portfolio of integrated products to address the rapidly growing cancer and
infectious disease diagnostic and research markets using tissue immunostaining
and in situ hybridization methods. Biocare Medical is headquartered and has
manufacturing facilities in Concord, California, and has a global distribution
network. For more information, please visit

About AsymmetRx Medical
AsymmetRx Medical, Inc. is privately held and was founded in 2001 by
scientists from Harvard University and Johns Hopkins University to develop
novel diagnostics, imaging agents, and therapies for urologic cancers
including those affecting the bladder and prostate. Using strategies based on
key advisors from private and academic clinicians and pathologists
specializing in urologic cancers, AsymmetRx is committed to developing the
most accurate tests for the analysis of prostate and bladder biopsies, as well
as early detection tests that in the future will obviate the need for needle
biopsies. AsymmetRx is committed to developing systems of imaging urologic
cancers that will aid in the early treatment of such diseases, as well as
therapies based on specific targeting of malignant cells in urologic cancers.
The Wall Street Journal recognized AsymmetRx for one of the "Best
Technologies" in the Biotech medical field in 2005. AsymmetRx succeeded in
developing the first FDA cleared test for prostate cancer in needle biopsies
based on the p63 antibody. It is anticipated that the p63-based test will
assist in the accurate diagnosis and treatment of hundreds of thousands of men
in the United States alone. More detailed information on the company and its
mission may be found at

© 2013 Ventana Medical Systems, Inc.
VENTANA and the VENTANA Logo are trademarks of Roche.
All other trademarks are the property of their respective owners.

SOURCE Ventana Medical Systems, Inc.

Press spacebar to pause and continue. Press esc to stop.